

ASIC consent to resignation of auditor

ITL Health Group Limited (ASX: ITD) (the Company) at its recent AGM on 26 October 2018 received approval from its shareholders to appoint Nexia Sydney Auditors P/L as the Company's auditors subject to ASIC approval. ASIC has advised it consents to the resignation, effective as of this disclosure, and subject to the company making the following disclosures:

Details of Outgoing auditor: Ernst & Young

Details of the proposed auditor: Nexia Sydney Auditors P/L

The reason for change in auditor: To appoint auditors more attuned to the company's needs and who would be able to prioritise these needs, as well as for cost efficiencies.

About ITL Health Group www.itlhealthgroup.com

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.

ITL Health Group

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.



Ranked 16th most Innovative Company by the
AFR Innovative Companies Awards

Australian Securities Exchange

Code: ITD

Ordinary Shares

85,552,339

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Chief Financial Officer & Company Secretary
---------------	--

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 9088 7991
Email:	info@itlhealthgroup.com
Address:	Level 3, 10 Moore Street, Canberra, ACT 2601

www.itlhealthgroup.com

Media

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.co.au